Oasmia Pharmaceutical AB, Sweden and Medison Pharma, Israel announce license and distribution agreement for Paclical® in Israel and Turkey
Medison is an Israeli pharmaceutical company with about 140 employees. The company specializes in niched pharmaceuticals and has several strong partners.
This is the second agreement for Paclical®. Oasmia has previously closed a license and distribution agreement for the Nordics with Orion Corporation, Finland.
- We are very pleased to announce a new agreement for Paclical. Medison is a highly regarded company in their region and our cooperation will be very beneficial to the continued development of Oasmia, comments Oasmia's CEO Julian Aleksov.
- We are proud to expand our portfolio with Paclical. It will be part of our vast Oncology line and it's a great annunciation for the patients and health community in Israel and Turkey. We are delighted to collaborate in Turkey with Gen Ilac, a leading company with whom we have enjoyed a long term collaboration, comments Medison's President & CEO Meir Jakobsohn.
With the retinoid based unique platform XR-17, Oasmia has managed to develop a water soluble formulation of Paclitaxel (Paclical®) that does not require premedication, allows a significantly higher dose and shows a different side effect profile compared to Taxol®. The main indications are ovarian cancer and lung cancer.
Medison Pharma Ltd, headquartered in Petach Tikva, Israel, is Israel's leading marketing group, representing innovative pharmaceuticals, medical devices and diagnostic products. Medison provides the complete spectrum of integrated services for international companies looking to enter or expand their presence in the Israeli, Romanian and Slovakian healthcare markets. Medison has long term collaborations with companies such as Amgen, Biogen, Shire, Ipsen and Boston scientific. Medison employs a comprehensive approach to sales and service, supplying HMOs (Health Maintenance Organizations), Medical Centers and physicians. Aligned with the growing trend toward integrating pharmaceuticals, medical devices and diagnostics, Medison is taking a leading role in advancing personalized medicine and healthcare toward more focused practice and treatment paradigms.
Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops a new generation of drugs within human and veterinary oncology. The product development aims to manufacture novel formulations based on well-established cytostatics which, in comparison with current alternatives, show improved properties, a reduced side-effect profile and an expanded therapeutic area The company has developed several unique formulations based on the platform XR-17: Paclical® (paclitaxel), Doxophos® (doxorubicin), Docecal® (docetaxel) and Carbomexx® (carboplatin). The product development is based on in-house research within nanotechnology and company patents. The company was registered in 1999 and is located in Uppsala, Sweden.